Michael Shawn Moran - Sep 27, 2021 Form 3 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Role
EVP, Chief Commercial Officer
Signature
/s/ Brian Cahill, Attorney-in-Fact
Stock symbol
EGRX
Transactions as of
Sep 27, 2021
Transactions value $
$0
Form type
3
Date filed
10/7/2021, 07:03 PM
Next filing
Jan 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EGRX Common Stock 24.3K Sep 27, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EGRX Employee Stock Option (right to buy) Sep 27, 2021 Common Stock 10K $66.32 Direct F2
holding EGRX Employee Stock Option (right to buy) Sep 27, 2021 Common Stock 27K $84.92 Direct F2
holding EGRX Employee Stock Option (right to buy) Sep 27, 2021 Common Stock 5K $59.14 Direct F3
holding EGRX Employee Stock Option (right to buy) Sep 27, 2021 Common Stock 1.59K $41.37 Direct F4
holding EGRX Employee Stock Option (right to buy) Sep 27, 2021 Common Stock 37.5K $59.79 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20,828 of the shares represent restricted stock units ("RSU") awards. The RSUs shall vest: 253 RSUs on January 7, 2022; 563 RSUs on January 29, 2022; 562 RSUs on January 29, 2023; 3,750 RSUs on each of January 5, 2022, January 5, 2023 and January 5, 2024; and 2,050 RSUs on each of February 2, 2022, February 2, 2023, February 2, 2024 and February 2, 2025, subject to the Reporting Person's continuous service through each vesting date.
F2 The options are fully vested and exercisable.
F3 One fourth (1/4th) of the shares underlying the option vested on January 7, 2019, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.
F4 The option grant was initially 4,500 shares of which one fourth (1/4th) of the shares underlying the option vested on January 29, 2020, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.
F5 One fourth (1/4th) of the shares underlying the option vested on January 5, 2021, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.